Mednet Logo
HomeNeurology
Neurology

Neurology

Expert perspectives on neurological conditions, stroke management, movement disorders, and neuromuscular disease.

Recent Discussions

How do you mitigate the risk of rebound disease activity when discontinuing S1p inhibitors or Tysabri in patients with multiple sclerosis?

1 Answers

Mednet Member
Mednet Member
Neurology · UTHealth

While there is no ideal method as determined by well-designed randomized studies, two options would be: (a) steroid bridge between therapies and (b) minimize wash-out period between switches. For many DMTs, a wash-out period between drugs is not needed. If the question regarding the S1p inhibitor wa...

How do you implement antipsychotics in the management of agitation in Alzheimer’s patients?

4
3 Answers

Mednet Member
Mednet Member
Psychiatry · Hebrew Seniorlife

The answer to how you implement antipsychotic medication in the management of agitation in a patient with Alzheimer's dementia involves several steps, outlined here: Ensure the agitation is not related to an acute medical condition and/or delirium. In this case, it is important to treat the underlyi...

What nutritional supplements do you recommend for patients with ALS?

2 Answers

Mednet Member
Mednet Member
Neurology · University of Utah

I do not recommend specific supplements. If the question relates to the PEG formula, we use basic formulas and higher caloric versions if needed.

In what clinical situations do you switch to Vyalev in patients with Parkinson's disease?

1
3 Answers

Mednet Member
Mednet Member
Neurology · VUMC Neurology

Vyalev (foscarbidopa/foslevodopa) administered by subcutaneous infusion with an external battery-operated pump, was recently FDA-approved. Conceptually, it offers the prospect of continuous levodopa administration which should improve dyskinesia and motor fluctuations. Skin reactions can be problema...

Would you add immunosuppression in ocular myasthenia gravis patients who are symptomatically well-controlled on pyridostigmine?

3
1 Answers

Mednet Member
Mednet Member
Neurology · University of Minnesota

This requires a shared decision-making approach with the patient because there is no right or wrong answer/choice. Although it has never been demonstrated in a placebo-controlled blinded study, I do believe (for years now) that low-dose prednisone can reduce the risk of generalization of ocular MG.A...

What treatments options may be considered in patients with POTS who also need daily diuretics to treat heart failure and are already wearing compression garments?

7
3 Answers

Mednet Member
Mednet Member
Cardiology · Vanderbilt Heart And Vascular Institute

Given the epidemiology of POTS and congestive heart failure, you are far more likely to see a patient with neurogenic orthostatic hypotension and CHF than POTS and CHF. I have an article on NOH and CHF in Autonomic Neuroscience 2020. The principals are basically the same however because the managem...

What are preferred sleep aids in elderly patients with dementia?

3
6 Answers

Mednet Member
Mednet Member
Psychiatry · University of New Mexico Medical School

Melatonin 3-6 mg because of their loss of melatonin-secreting potency with age. Doxepin 10 mg because of the cost of 3 and 6 mg versions. If restless legs or limb movements during sleep, gabapentin or pregabalin. Pregabalin can be better tolerated with less next-day sedation (also can be an issue wi...

Is there a utility in getting repeat antibody testing on GBS patients after PLEX?

1 Answers

Mednet Member
Mednet Member
Neurology · University of Minnesota

No, there is not, for a couple of reasons: Most patients with the most common variant of GBS (AIDP) are negative for ganglioside antibodies or other antibodies against nodal/paranodal proteins. Ganglioside antibodies are more often positive in GBS variants like AMAN, AMSAN, Miller Fisher syndrome, s...

How would you approach the decision to escalate DMT in a patient with relapsing multiple sclerosis who has two to three new T2 lesion but no clinical symptoms?

1
1 Answers

Mednet Member
Mednet Member
Neurology · Yale University School of Medicine

I would escalate to higher-efficacy DMT in this scenario. As highlighted in the linked article, new T2 lesions show that the patient is at heightened risk for clinical relapses and their disease activity is not well controlled. In the linked study, included patients were on low efficacy DMT (interfe...

How long after a motor vehicle accident would you expect symptoms including memory loss, hypersomnia, and mood changes to be attributable to the accident?

1
1 Answers

Mednet Member
Mednet Member
Neurology · Champlain Pain Relief & Neurology

I would love to have the answer to this. I can tell you what the Headache Classification Committee of the International Headache Society says:Post-traumatic headache (PTHA) is defined as a secondary headache that develops within 7 days after head trauma (or after regaining consciousness following he...